Ajanta Pharma Ltd
Ajanta Pharma Ltd Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book
Q1 FY27 earnings call: what management guided on revenue, margins and order book.
The short version
The provided document is a cover letter for the earnings call transcript dated 30th July 2026; it does not contain detailed discussions or statements on future growth expectations in sales, revenue, or volumes. The provided document is a cover letter regarding the written transcript of Ajanta Pharma’s earnings call held on 30th July 2026.
From Ajanta Pharma Ltd's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Revenue & Sales Performance
Profitability & Margins
See what Ajanta Pharma Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Ajanta Pharma Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Ajanta Pharma Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹1.4K Cr, net profit ₹267 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Ajanta Pharma Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- IOL Chemicals (Q1 FY27)
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
- Innova Captab Ltd (Q1 FY27)
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
- Glenmark Pharma. (Q1 FY27)
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…
- Strides Pharma Science Ltd (Q1 FY27)
markets continue to be broad-based growth drivers, with 17% YoY growth and expansion in B2B and B2C markets including Europe, UK, Nordics, Africa, LATAM, MENA…
Frequently Asked Questions
What were Ajanta Pharma Ltd Q1 FY27 results?
The provided document is a cover letter for the earnings call transcript dated 30th July 2026; it does not contain detailed discussions or statements on future growth expectations in sales, revenue, or volumes. The provided document is a cover letter regarding the written transcript of Ajanta Pharma’s earnings call held on 30th July 2026.
What is Ajanta Pharma Ltd share price analysis?
Ajanta Pharma Ltd currently shows a neutral. The stock trades at a P/E of 40.1 with a market cap of ₹45,483 Cr. Investors should review the full earnings analysis for detailed insights.
Is Ajanta Pharma Ltd planning capital expenditure?
The provided document is a cover letter for the written transcript of Ajanta Pharma's earnings call held on 30th July 2026.
Keep Ajanta Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.